NuVision Competitors and Similar CompaniesClear all
NuVision's competitors and similar companies include aTyr Pharma, Kuros Biosciences, Alnylam Pharmaceuticals and Oxurion.
 Kuros Biosciences Kuros Biosciences is a biopharmaceutical company that engages in the development of biopharmaceutical products for tissue repair and bone regeneration. |  Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. |  Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. | |||
Founding Date | Founding Date 2015 | Founding Date 2005 | Founding Date 2000 | Founding Date 2002 | Founding Date 1991 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Nottingham, GB HQ | Locations San Diego, US HQ | Locations Zürich, CH HQ Bilthoven, NL Boston, US | Locations Leuven, BE HQ Dublin 8, IE | |
Employees | Employees 20 | Employees 4235% decrease | Employees 80 | Employees 1,32324% increase | Employees 785% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 131.1 m | Valuation ($) N/A | Valuation ($) 33.6 b | Valuation ($) 1 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $353k (FY, 2023) | Revenue (est.) CHF33.6m (FY, 2023) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) €263k (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods CHF3m (FY, 2023) | Cost of goods $268.2m (FY, 2023) | Cost of goods €159k (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit CHF30.8m (FY, 2023) | Gross profit $1.6b (FY, 2023) | Gross profit €2.1m (FY, 2023) |
Net income | Net income N/A | Net income ($50.4m) (FY, 2023) | Net income (CHF13.7m) (FY, 2023) | Net income ($440.2m) (FY, 2023) | Net income (€19m) (FY, 2023) |
Funding | |||||
Total funding raised | Total funding raised $ 3m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 1.5b | Total funding raised $ 3.9m |
For sources of this data, please see the company profile
View Company Profiles
aTyr Pharma
HQ
San Diego, US
Employees
42↓ 35% decrease
aTyr Pharma discovers and develops protein biologics for human therapeutics.
View companyKuros Biosciences
HQ
Zürich, CH
Employees
80
Kuros Biosciences is a biopharmaceutical company that engages in the development of biopharmaceutical products for tissue repair and bone regeneration.
View companyAlnylam Pharmaceuticals
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
View companyOxurion
HQ
Leuven, BE
Employees
78↑ 5% increase
Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye.
View company